Systemic immunomodulatory therapy in the management of atopic dermatitis: the value of Tralokinumab

Abstract

Atopic dermatitis is a chronic inflammatory skin disease that substantially impacts the quality of life and functional capacity of those who suffer from it. In the midst of describing the pathogenesis and pathophysiology of this condition, the aberrant activity of interleukins (ILs) stands out, mainly IL-13 type 2. Currently, there is no definitive and safe treatment to address this disease. Traditionally, antibiotic therapy and corticosteroids have been indicated, but given the adverse effects commonly reported with these drugs, it is not reproducible or safe to continue with these regimens. Over the last few years, some agents with immunomodulatory potential have been proposed, which could change the course of atopic dermatitis. Within the global health objectives stipulated for the year 2030, there is the need to develop drugs that allow control of the burden of diseases that generate pathological entities that considerably affect both the quality of life and the catastrophic expense of the global population. with main emphasis on low- and middle-income countries, where difficulties prevail for timely and effective access to health services and targeted treatments. Therefore, the effort to find an agent that regulates chronicity or solves this disease is a priority both for dermatology and for global health.